Aspirin Cuts Dementia Risk 70% — But Only in One Genetic Group
By @sharedot · · 7 pages
- Health
- Dementia
- Aspirin
- Genetics
- Medical Research
Low-dose aspirin cut dementia risk 70% in high-platelet-genetic-score people in Monash's ASPREE analysis, but doubled bleeding risk.
A 70% Lower Dementia Risk in a Specific Genetic Group
Researchers at Monash University analyzed genetic data from more than 13,500 participants in the landmark ASPREE trial (Aspirin in Reducing Events in the Elderly) and found that low-dose aspirin was linked to a dramatically lower dementia risk in a subset of older adults.
Among people in the top 20% of genetic scores associated with platelet count, just 1% of aspirin users developed dementia, compared with 3.3% of those taking a placebo — roughly a 70% lower relative risk.
The findings were published in *Alzheimer's & Dementia: The Journal of the Alzheimer's Association*.
Lead author Dr. Peter Fransquet, a Research Fellow at Monash's School of Public Health and Preventive Medicine, said previous trials found no protective effect when everyone was considered together, but 'in people with this particular genetic profile, we saw substantially fewer cases of dementia among those taking aspirin.'
Why This Is Surprising: The One-Size-Fits-All Result Breaks Down
The result is a consensus-breaking finding. Earlier trials concluded aspirin did not prevent dementia overall, which is why no doctor recommends it for that purpose.
This new analysis suggests the drug's effect may vary sharply by genetic makeup, pointing toward personalized prevention rather than a blanket approach. Equally surprising, the genetic signal did not involve the well-established genetic risk factors for Alzheimer's disease.
'Instead, it's pointing us towards platelet biology and gives us a new avenue to investigate,' Dr. Fransquet said, noting that prior research has connected dementia with platelet activation and aggregation, but the role of overall platelet count was far less understood.
That a cheap, widely available drug might work selectively — visible only once genes were factored in — is the kind of nuance population-level trials can easily miss.
The Catch: Major Bleeding Risk Doubled
The potential benefit came with a dangerous trade-off. In the same high-scoring genetic group, 4.4% of aspirin users experienced major bleeding, compared with 2.1% of those on placebo — meaning the apparent dementia protection was accompanied by roughly double the rate of serious bleeding events.
The researchers emphasized that people should not start taking aspirin to prevent dementia on the basis of this study without consulting their doctor, particularly given the increased bleeding risk.
Previous Monash work has already flagged aspirin's downsides in healthy older adults: ScienceDaily reports a large Monash study found daily aspirin raised anemia risk by 20% in adults aged 70 and older.
Any benefit in cognition would have to be weighed against these real, measurable harms before the finding could shape medical guidance.
The Stakes as Dementia Cases Climb
The implications are significant because dementia is becoming far more common. Dementia Australia estimates that approximately 446,500 people in Australia were living with the condition in 2026, a number expected to exceed one million by 2065.
If the genetic association holds, the researchers note that aspirin's low cost and wide availability could make personalized dementia prevention a realistic possibility — a preventive strategy accessible at scale, unlike many experimental dementia therapies.
The prospect of using genetic testing to identify who might benefit, rather than treating everyone the same, could reshape how prevention trials are designed and interpreted across medicine.
Dr. Fransquet said genetics 'could one day help us identify who may benefit from a preventive treatment, rather than taking a one-size-fits-all approach.'
What Comes Next: Confirmation and a Targeted Trial
The findings must be confirmed before they can guide medical recommendations.
According to the researchers, the next step is to investigate whether the association appears in other populations; scientists would then need to conduct a clinical trial specifically involving people with the genetic profile identified in the analysis.
ua.news reports that the identified genetic association was not related to established genetic risk factors for Alzheimer's and other dementias, but instead indicates a need for further study of platelet biology.
Until such targeted trials are run, the results remain an intriguing hypothesis rather than advice.
The study's authors cautioned against starting aspirin for dementia prevention based on this study alone, and the practical route forward runs through a doctor's consultation — not the pharmacy aisle — while researchers test whether genes can indeed sort benefit from bleeding risk.